Business
Isodiol International Inc. Announces Closing of Strategic Non-Brokered Offering for Total Proceeds of $18 Million
Isodiol International Inc. Announces Closing of Strategic Non-Brokered Offering for Total Proceeds of $18 Million.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, May 28, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical and health and wellness products and now supporting the pharmaceutical industry at large with its recently approved CBD as an Active Pharmaceutical Ingredient, announces the closing of the strategic non-brokered private placement, for total proceeds of $18,000,000. \n “We are extremely pleased to close this strategic investment,” said CEO of Isodiol, Marcos Agramont.  “With this additional funding, the Company is now well positioned to further execute its plan of aggressive global expansion and also continue to be a global CBD innovator. International markets present many opportunities for the Company including new market channels, university collaborations, clinical studies, and ultimately, increased revenues.”  The Company will use the proceeds of the Private placement primarily for global expansion, including the recently announced expansion in the UK and China.   For more information on Isodiol, please visit www.isodiol.com About Isodiol International Inc. Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe. Join Us On Facebook: https://www.facebook.com/isodiol/Twitter: @isodiol  ON BEHALF OF THE BOARDMarcos Agramont, CEO & Director INVESTOR RELATIONS:[email protected] Forward-Looking Information: This news release contains \"forward-looking information\" with...